KALA BIO, INC. Expense Related to Distribution or Servicing and Underwriting Fees
KALA BIO, INC. (KALA) reported Expense Related to Distribution or Servicing and Underwriting Fees of $8.47 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees · last filed 2022-03-29
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for the quarter ending 2020-12-31 was $0.00.
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for the quarter ending 2020-06-30 was $464.00K.
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for the quarter ending 2020-03-31 was $8.01M.
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for fiscal 2020 was $8.47M.
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for fiscal 2018 was $5.00M, a 47.34% decline from fiscal 2017.
- KALA BIO, INC. expense related to distribution or servicing and underwriting fees for fiscal 2017 was $9.49M.
| Period end | Expense Related to Distribution or Servicing and Underwriting Fees 3 month | Expense Related to Distribution or Servicing and Underwriting Fees 3 month as first filed | Expense Related to Distribution or Servicing and Underwriting Fees 6 month | Expense Related to Distribution or Servicing and Underwriting Fees 6 month as first filed | Expense Related to Distribution or Servicing and Underwriting Fees 9 month | Expense Related to Distribution or Servicing and Underwriting Fees 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $464.00K derived: sum of 3 quarters · filed 2022-03-29 | $8.47M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $464.00K derived: sum of 2 quarters · filed 2021-11-15 | $8.47M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $464.00K 10-Q · filed 2021-08-05 | $500.00K 10-Q · filed 2020-08-06 | $8.47M 10-Q · filed 2021-08-05 | $8.10M 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | $8.01M 10-Q · filed 2021-05-05 | $8.10M 10-Q · filed 2020-05-07 | ||||
| 2019-09-30 | $66.00K 10-Q · filed 2020-11-05 | $66.00K 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $5.00M 10-K · filed 2020-02-12 | |||||
| 2017-12-31 | $9.49M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |